Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVGR OTCMKTS:ECIA NASDAQ:LLIT NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$0.47$0.47$0.36▼$1.93$1.57M1.291.46 million shsN/AECIAEncision$0.28$0.33$0.10▼$0.50$4.73M0.781,656 shsN/ALLITLianluo Smart$47.22+1.9%$9.91$2.76▼$17.14$104.40M0.161.04 million shs984,843 shsPSTVPlus Therapeutics$0.62+1.0%$0.56$0.16▼$2.31$61.54M0.8145.31 million shs4.90 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger0.00%0.00%0.00%0.00%-47.54%ECIAEncision0.00%-22.43%-21.35%-23.50%-40.18%LLITLianluo Smart+1.90%+2.23%+0.21%+59.80%+6,833.92%PSTVPlus Therapeutics0.00%-11.17%+43.82%+66.89%-56.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$0.47$0.47$0.36▼$1.93$1.57M1.291.46 million shsN/AECIAEncision$0.28$0.33$0.10▼$0.50$4.73M0.781,656 shsN/ALLITLianluo Smart$47.22+1.9%$9.91$2.76▼$17.14$104.40M0.161.04 million shs984,843 shsPSTVPlus Therapeutics$0.62+1.0%$0.56$0.16▼$2.31$61.54M0.8145.31 million shs4.90 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger0.00%0.00%0.00%0.00%-47.54%ECIAEncision0.00%-22.43%-21.35%-23.50%-40.18%LLITLianluo Smart+1.90%+2.23%+0.21%+59.80%+6,833.92%PSTVPlus Therapeutics0.00%-11.17%+43.82%+66.89%-56.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVGRAvinger 0.00N/AN/AN/AECIAEncision 0.00N/AN/AN/ALLITLianluo Smart 0.00N/AN/AN/APSTVPlus Therapeutics 3.00Buy$8.001,190.32% UpsideCurrent Analyst Ratings BreakdownLatest AVGR, ECIA, PSTV, and LLIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025PSTVPlus TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025PSTVPlus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/6/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.50 ➝ $21.009/27/2025PSTVPlus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/25/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/18/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/3/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/3/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$5.008/18/2025PSTVPlus TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.00(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVGRAvinger$7.65M0.21N/AN/A($4.53) per share-0.10ECIAEncision$6.55M0.72N/AN/A$0.14 per share2.00LLITLianluo Smart$380K274.75N/AN/A($0.59) per share-80.03PSTVPlus Therapeutics$5.82M10.57N/AN/A($1.52) per share-0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVGRAvinger-$18.32M-$11.06N/AN/AN/AN/AN/AN/AN/AECIAEncision-$220K-$0.02N/A∞N/A-4.34%-16.99%-7.45%11/12/2025 (Estimated)LLITLianluo Smart-$4.45MN/A0.00∞N/AN/AN/AN/AN/APSTVPlus Therapeutics-$12.98M-$2.24N/AN/AN/A-357.85%N/A-117.72%11/13/2025 (Estimated)Latest AVGR, ECIA, PSTV, and LLIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025PSTVPlus Therapeutics-$0.02N/AN/AN/A$1.50 millionN/A8/14/2025Q2 2025PSTVPlus Therapeutics-$0.09-$0.01+$0.08-$0.01$1.08 million$1.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVGRAvingerN/AN/AN/AN/AN/AECIAEncisionN/AN/AN/AN/AN/ALLITLianluo SmartN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVGRAvingerN/AN/AN/AECIAEncision0.101.920.72LLITLianluo SmartN/A2.422.17PSTVPlus TherapeuticsN/A1.261.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVGRAvinger18.30%ECIAEncision8.20%LLITLianluo Smart28.75%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipAVGRAvinger42.80%ECIAEncision36.75%LLITLianluo Smart22.90%PSTVPlus Therapeutics0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVGRAvinger703.31 million1.89 millionNot OptionableECIAEncision3016.88 million10.68 millionNot OptionableLLITLianluo Smart62.21 millionN/ANot OptionablePSTVPlus Therapeutics2099.26 million98.48 millionNot OptionableAVGR, ECIA, PSTV, and LLIT HeadlinesRecent News About These CompaniesPlus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest UpdateOctober 18 at 5:14 AM | marketbeat.comPlus Therapeutics (NASDAQ:PSTV) Upgraded by Zacks Research to "Strong-Buy" RatingOctober 15, 2025 | marketbeat.com5 Small Drug Stocks to Buy as the Industry Shows Some RecoveryOctober 14, 2025 | zacks.comAnalysts Set Plus Therapeutics, Inc. (NASDAQ:PSTV) Price Target at $8.00October 12, 2025 | americanbankingnews.comPlus Therapeutics' (PSTV) Sell (E+) Rating Reaffirmed at Weiss RatingsOctober 10, 2025 | marketbeat.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Rating of "Moderate Buy" from BrokeragesOctober 7, 2025 | marketbeat.comAscendiant Capital Maintains Plus Therapeutics (PSTV) Buy RecommendationOctober 6, 2025 | msn.comPlus Therapeutics (NASDAQ:PSTV) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst SaysOctober 6, 2025 | marketbeat.comPlus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United HealthcareSeptember 26, 2025 | insidermonkey.comD. Boral Capital Maintains Plus Therapeutics (PSTV) Buy RecommendationSeptember 25, 2025 | msn.comThese 3 Penny Stocks are Soaring Today: PLUS, EVAX, DVLTSeptember 25, 2025 | 247wallst.comPlus Therapeutics Pops on UNH PactSeptember 25, 2025 | baystreet.caPlus Therapeutics Shares Surge After UnitedHealthcare Coverage DealSeptember 25, 2025 | msn.comPlus Therapeutics stock soars after UnitedHealthcare agreementSeptember 25, 2025 | za.investing.comPlus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerSeptember 25, 2025 | globenewswire.comPlus on Upside on Cancer Institute PaymentSeptember 22, 2025 | baystreet.caPlus Therapeutics announces $1.9M advance payment from CPRITSeptember 22, 2025 | msn.comPlus Therapeutics receives $1.9M CPRIT payment for cancer programSeptember 22, 2025 | msn.comPlus Therapeutics, Inc. Secures $1.9 Million Payment from CPRIT as Part of $17.6 Million Grant for Leptomeningeal Cancer Treatment DevelopmentSeptember 22, 2025 | quiverquant.comQPlus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRITSeptember 22, 2025 | globenewswire.comPlus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical LaboratorySeptember 18, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025How The Weak Dollar Is Fueling These Global Stock SurgesBy Gabriel Osorio-Mazilli | September 22, 2025CoreWeave: Why the New King of AI Infrastructure Has Room to RunBy Jeffrey Neal Johnson | October 1, 2025AVGR, ECIA, PSTV, and LLIT Company DescriptionsAvinger NASDAQ:AVGRAvinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.Encision OTCMKTS:ECIA$0.28 0.00 (0.00%) As of 10/17/2025Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.Lianluo Smart NASDAQ:LLITLianluo Smart Limited, together with its subsidiaries, designs, develops, markets, and distributes medical products primarily in China and internationally. The company offers medical devices, including wearable sleep respiratory solutions, general hospital products, medical compressors, and related supporting products. It also provides technical services in relation to the detection and analysis of obstructive sleep apnea syndrome to hospitals and medical centers through medical wearable devices. In addition, the company distributes medical products, such as sleep apnea machines. Lianluo Smart Limited sells its products primarily through distributors; and directly to hospitals, physical examination centers, and sleep centers, as well as to individual consumers. The company was formerly known as Dehaier Medical Systems Limited and changed its name to Lianluo Smart Limited in November 2016. Lianluo Smart Limited was incorporated in 2003 and is headquartered in Beijing, China.Plus Therapeutics NASDAQ:PSTV$0.62 +0.01 (+0.96%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.61 -0.01 (-1.94%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
